Do the results of the new trials change the standard treatment of metastatic renal cell cancer?

Onkologie

Volumn 30, Issue 5, 2007, Pages 260-264

  Mulder, Sasja F ^a   Van Spronsen, Dick Johan ^a   De Mulder, Pieter H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis inhibitor; Metastasized; Prognosis; Renal cell carcinoma; Survival

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ANEMIA; BONE MARROW SUPPRESSION; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; COST OF ILLNESS; DESQUAMATION; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; DRUG MISUSE; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; LEUKOPENIA; MEDICAL RESEARCH; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; PERIPHERAL EDEMA; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; THYROIDITIS; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CLINICAL TRIALS; CYTOKINES; DRUG COSTS; HUMANS; INDOLES; KIDNEY NEOPLASMS; LONG-TERM CARE; LUNG NEOPLASMS; PYRIDINES; PYRROLES; SIROLIMUS; SURVIVAL RATE;

EID: 34247631240     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000101194     Document Type: Review

References (26)

1. Van Spronsen D, De Mulder P: Targeted approaches for treating advanced clear cell carcinoma. Onkologie 2006;29:394-402.
2. Cohen H, McGovern F: Renal cell carcinoma. N Engl J Med 2005;353:3477-3490.
3. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;1:CD001425.
4. Lopez Hanninen E, Kirchner H, Atzpodien J: Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 1996;155:19-25.
5. Elson PJ, Witte RS, Trump DL: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988;48:7310-7313.
6. Palmer PA, Vinke J, Philip T, et al.: Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992;3:475-480.
7. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-2540.
8. Fossa S, Jones M, Johnson P, et al.: Interferon-alpha and survival in renal cell cancer. Br J Urol 1995;76:286-290.
9. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-463.
10. Negrier S, Perol D, Ravaud A, et al.: Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Resultsof the prospective randomized PERCY Quattro trial. J Clin Oncol, Proc Am Soc Clin Oncol 2005;23:LBA4511.
11. Atkins M, Regan M, McDermott D, et al.: Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11:3714-3721.
12. Bui MH, Seligson D, Han KR, et al.: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003;9:802-811.
13. Rini BI, Weinberg V, Dunlap S, et al.: Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 2006;106:566-575.
14. Donskov F, von der Maase H: Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006;24:1997-2005.
15. Interim analysis of phase III trial shows avastin plus interferon therapy improved progression-free survival in patients with previously untreated advanced renal cell carcinoma. http://www.gene.com/gene/news/press-releases/ display.do?method=detail&id=10227.
16. Motzer RJ, Michaelson MD, Redman BG, et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Onc 2006;24:16-24.
17. Motzer RJ, Rini BI, Bukowski RM, et al.: Sunitinib in patients with metastatic renal cell carcinoma. Jama 2006;295:2516-2524.
18. Motzer RJ, Hutson TE, Pharm D, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124
19. Ratain MJ, Eisen T, Stadler WM, et al.: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512.
20. Escudier B, Eisen T, Stadler WM, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007:356:125-134.
21. Dutcher JP: Mammalian target of rapamycin inhibition. Clin Cancer Res 2004;10:6382S-6387S.
22. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al.: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-918.
23. Smith JW, Ko YJ, Dutcher J, et al.: Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-? to patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 2004;22(suppl 14):4513.
24. Hudes G, Carducci M, Tomczak P, et al.: A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 2006;24:2s(abstr LBA4).
25. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK: Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006; 145:660-664.
26. Rini BI, George DJ, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Margolin K, Hutson TE, Baum CM: Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (MRCC). Ann Oncol 2006;17(suppl 9):abstr 4380.